Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca2+-sensitivity and suppress the modulation of Ca2+-sensitivity by troponin I phosphorylation by Messer, A et al.
lable at ScienceDirect
Archives of Biochemistry and Biophysics 601 (2016) 113e120Contents lists avaiArchives of Biochemistry and Biophysics
journal homepage: www.elsevier .com/locate/yabbiMutations in troponin T associated with Hypertrophic
Cardiomyopathy increase Ca2þ-sensitivity and suppress the
modulation of Ca2þ-sensitivity by troponin I phosphorylation*
Andrew E. Messer a, *, Christopher R. Bayliss a, Mohammed El-Mezgueldi b,
Charles S. Redwood c, Douglas G. Ward d, Man-Ching Leung a, Maria Papadaki a,
Cristobal dos Remedios e, Steven B. Marston a
a Imperial College London, London, UK
b University of Leicester, Leicester, UK
c University of Oxford, Oxford, UK
d University of Birmingham, Birmingham, UK
e University of Sydney, Sydney, Australiaa r t i c l e i n f o
Article history:
Received 3 November 2015
Received in revised form
16 March 2016
Accepted 26 March 2016
Available online 29 March 2016
Keywords:
Hypertrophic Cardiomyopathy
Troponin T
Phosphorylation of troponin I
Ca2þ regulation of contractility
In vitro motility assayAbbreviations: DCM, Dilated Cardiomyopathy;
Gallate; HCM, Hypertrophic Cardiomyopathy; IVMA,
Rate of force development; kREL, Rate of fast relaxatio
TnC, Troponin C; TnI, Troponin I; TnT, Troponin T; W
* This article is part of a Special Issue entitled Myoﬁ
Contraction, edited by Brandon J. Biesiadecki.
* Corresponding author. National Heart and Lun
London, Myocardial Function, Imperial Centre for Tra
Medicine, Hammersmith Campus, Du Cane Road, Lon
E-mail address: a.messer@imperial.ac.uk (A.E. Mes
http://dx.doi.org/10.1016/j.abb.2016.03.027
0003-9861/© 2016 The Authors. Published by Elseviera b s t r a c t
We investigated the effect of 7 Hypertrophic Cardiomyopathy (HCM)-causing mutations in troponin T
(TnT) on troponin function in thin ﬁlaments reconstituted with actin and human cardiac tropomyosin.
We used the quantitative in vitro motility assay to study Ca2þ-regulation of unloaded movement and its
modulation by troponin I phosphorylation. Troponin from a patient with the K280N TnT mutation
showed no difference in Ca2þ-sensitivity when compared with donor heart troponin and the Ca2þ-
sensitivity was also independent of the troponin I phosphorylation level (uncoupled). The recombinant
K280N TnT mutation increased Ca2þ-sensitivity 1.7-fold and was also uncoupled. The R92Q TnT mutation
in troponin from transgenic mouse increased Ca2þ-sensitivity and was also completely uncoupled. Five
TnT mutations (D14, D28 þ 7, DE160, S179F and K273E) studied in recombinant troponin increased Ca2þ-
sensitivity and were all fully uncoupled. Thus, for HCM-causing mutations in TnT, Ca2þ-sensitisation
together with uncoupling in vitro is the usual response and both factors may contribute to the HCM
phenotype. We also found that Epigallocatechin-3-gallate (EGCG) can restore coupling to all uncoupled
HCM-causing TnT mutations. In fact the combination of Ca2þ-desensitisation and re-coupling due to
EGCG completely reverses both the abnormalities found in troponin with a TnT HCM mutation sug-
gesting it may have therapeutic potential.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hypertrophic cardiomyopathy (HCM) is the most common
inherited cardiomyopathy and is usually associated with mutationsEGCG, Epigallocatechin-3-
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Inc. This is an open access article uin sarcomeric proteins. A recent study has shown that 11% of the
identiﬁed mutations are in the proteins of the thin ﬁlament; actin,
tropomyosin, troponin I (TnI), troponin C (TnC) and troponin T
(TnT) [1]. It is generally found that HCM-causingmutations result in
a 2e3 fold higher myoﬁlament Ca2þ-sensitivity compared to
normal heart muscle and this has been proposed to be necessary to
trigger the symptoms of HCM: a hyper-contractile phenotype, heart
muscle hypertrophy, myocyte disarray and ﬁbrosis [2], although the
clinical manifestation of HCM is very variable, probably due to
background genetic and environmental factors.
Mutations in the same sarcomeric protein genes are also associ-
ated with familial dilated cardiomyopathy (DCM), a disease charac-
terised by a hypo-contractile phenotype with dilation of the heart
chamber and thinningof cardiacmuscle [3].WhilstDCMclearly has ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Effect of the HCM related TnT K280N mutation on Ca2þ-sensitivity and phosphorylation dependence of Ca2þ-sensitivity using the TnT K280N patient sample (see Fig. 1).
X ¼ exchanged. All data rounded to 2 signiﬁcant ﬁgures.
Experiment EC50, mM Ratio (EC50 Test/Control) n p TnI Phosphorylation
Test vs Control Test Control Test Control
A Donor vs K280N patient 0.19 ± 0.015 0.20 ± 0.016 0.99 ± 0.047 11 0.87 1.6 ± 0.060 1.4 ± 0.020
B K280N vs dpK280N patient 0.14 ± 0.022 0.14 ± 0.024 0.99 ± 0.020 6 0.54 1.4 ± 0.090 0.11 ± 0.10
C Donor vs dpDonor 0.14 ± 0.030 0.050 ± 0.010 3.1 ± 0.55 10 0.0040 1.6 ± 0.070 0.23 ± 0.070
D K280N patientXTnT vs dpK280N patientXTnT 0.16 ± 0.035 0.088 ± 0.013 1.8 ± 0.17 4 0.022 1.4 ± 0.12 0.090 ± 0.070
A.E. Messer et al. / Archives of Biochemistry and Biophysics 601 (2016) 113e120114separate molecular mechanism from HCM, the simple hypothesis
that Ca2þ-sensitivity is reduced in familial DCM (the opposite of
HCM) has proven to be incorrect since changes of Ca2þ-sensitivity do
not correlate with the phenotype [2,4,5]. Our investigations have
established that a consistent feature of DCM-causing mutations in
thinﬁlament proteins is that the Ca2þ-sensitivity is notmodulated byC
A
Fig. 1. Effect of the HCM related TnT K280N mutation (patient sample). The fraction of ﬁl
representative single experiments. The mean values of EC50 from replicate experiments are s
points, unphosphorylated troponin. Error bars represent SEM of four measurements of mo
patient thin ﬁlaments; green, WT TnT exchanged into TnT K280N patient thin ﬁlaments. A
sensitivity) was seen. B. Effect of phosphorylation on thin ﬁlaments containing the TnT K280
Effect of phosphorylation on donor thin ﬁlaments. Normal relationship as phosphorylatio
human cardiac TnT was exchanged into native TnT K280N patient thin ﬁlaments.TnI phosphorylation, a process we have called uncoupling, and we
have proposed that this is a disease-mechanism [4e6].
TnI is one of several substrates of protein kinase A (PKA). In
normal heart, on adrenergic stimulation PKA is activated and TnI
phosphorylation at Ser22 and 23 is increased. Phosphorylation of
TnI decreases myoﬁbrillar Ca2þ-sensitivity 2e3 fold andB
D
aments motile, measured in a paired experiment by IVMA, is plotted against [Ca2þ] for
hown in Table 1. Solid lines and points, phosphorylated troponin; dotted lines and open
tility in the same motility chamber. Blue, native donor thin ﬁlaments; red, TnT K280N
. Donor and TnT K280N patient containing thin ﬁlaments: no change in EC50 (Ca2þ-
N mutation. The relationship of Ca2þ-sensitivity to TnI phosphorylation is uncoupled. C.
n increased EC50. D. The difference in Ca2þ-sensitivity is restored when recombinant
A B C
Fig. 2. Effect of the HCM related TnT K280N mutation (recombinant protein). The fraction of ﬁlaments motile, measured in a paired experiment by IVMA, is plotted against
[Ca2þ] for representative single experiments. The mean values of EC50 from replicate experiments are shown in Table 2. Solid lines and points, phosphorylated troponin; dotted lines
and open points, unphosphorylated troponin. Error bars represent SEM of four measurements of motility in the same motility chamber. Blue, native donor thin ﬁlaments; purple,
donor thin ﬁlaments exchanged with recombinant human cardiac TnT K280N. A. Thin ﬁlaments containing donor troponin and donor troponin exchanged with recombinant human
cardiac TnT K280N show the difference in EC50 (Ca2þ-sensitivity) normally seen with HCM-causing mutations. B. Effect of phosphorylation on exchanged thin ﬁlaments containing
the recombinant human cardiac TnT K280N. The relationship of Ca2þ-sensitivity to TnI phosphorylation is uncoupled. C. Effect of 50% mutation. The difference in EC50 (decreased
Ca2þ sensitivity) is also seen with 50% exchanged thin ﬁlaments.
A.E. Messer et al. / Archives of Biochemistry and Biophysics 601 (2016) 113e120 115correspondingly increases the rate of Ca2þ dissociation from TnC.
This is an essential component of the lusitropic response to
adrenergic stimulation, consequently DCM mutations cause a
blunting of the response to b1 agonists, and this leads to a reduced
cardiac reserve and predisposes the heart to failure under stress [6].
Mutations in the cardiac TnT gene (TNNT2) are the most com-
mon HCM-causing mutations after MYH7 and MYBPC3. There have
been persistent reports from in vitro studies that HCM-causing
mutations in the other thin ﬁlament proteins: TnI, TnC, actin and
tropomyosin uncouple changes in myoﬁlament Ca2þ-sensitivity
from TnI phosphorylation level in addition to increasing absolute
Ca2þ-sensitivity (reviewed by Messer [5] and refs therein [7e17]).
However there have not been any systematic studies of mutations
in TnT associated with HCM. It is possible that uncoupling is a
consistent consequence of HCM-causing mutations in all thin ﬁla-
ment proteins and if so, it could contribute to the HCM phenotype.
In this study we investigate the relationship of myoﬁlament
Ca2þ-sensitivity toTnI phosphorylation in 7 HCM relatedmutations
in human cardiac TnT by quantitative in vitro motility assay. Six of
these are well-established mutations, whereas the seventh is a
unique human heart sample from an HCM patient with a homo-
zygous mutation, K280N. All these mutations induced uncoupling,
thus extending the range of cardiac disease associated with
uncoupling and raising the possibility of a physiological role in
accounting for the HCM phenotype.2. Methods
2.1. Sources of contractile proteins
Troponinwas isolated from human ormouse heart muscle usingTable 2
Effect of the HCM related TnT K280N mutation on Ca2þ-sensitivity and phosphoryla
X ¼ exchanged. All data rounded to 2 signiﬁcant ﬁgures.
Experiment EC50, mM
Test vs Control Test Control
A Donor vs DonorXK280N 0.17 ± 0.037 0.10 ± 0.020
B DonorXK280N vs dpDonorXK280N 0.10 ± 0.0050 0.098 ± 0.0050
C Donor v 50% DonorXK280N 0.14 ± 0.018 0.089 ± 0.0080an anti-cardiac troponin I (TnI) monoclonal antibody afﬁnity col-
umn as described [18]. We used heart muscle from TnT R92Q
transgenic mice and non-transgenic littermates [19] and explanted
heart from a patient with a homozygous TnT K280N mutation with
donor heart muscle as control [20]. Donor hearts had no history of
cardiac disease and normal ECG and ventricular function and were
obtained when no suitable transplant recipient was found.
Approval was granted by the Human Research Ethics Committees of
both the University of Sydney (Protocol No. 2814) and St. Vincent's
Hospital (Protocol No. H91/048/1a) for collection and distribution
of the human heart samples and by the NHS National Research
Ethics Service, South West London REC3 (10/H0803/147) for study
of the samples. Patients gave written consent with PIS approved by
the relevant ethical committee. All samples are anonymised. The
investigations conform to the principles of the Declaration of Hel-
sinki. Recombinant human cardiac TnT K280N (T3 isoform) was
introduced into donor heart troponin by exchange as described
[18]. Recombinant whole troponin incorporating HCM-causing
mutations in TnT (T3 isoform) was prepared as described [21,22].2.2. Manipulation and measurement of TnI phosphorylation level
Troponin isolated from human heart samples has a high level of
phosphorylation, which was reduced by treatment with shrimp
alkaline phosphatase (Sigma P9088). Recombinant TnI was phos-
phorylated by treatment with protein kinase A (PKA) catalytic
subunit (Sigma, P2645-400) as previously described [4,23]. TnI
phosphorylation levels in isolated troponin were measured by
phosphate afﬁnity SDS-PAGE as described by Messer et al. [24].tion dependence of Ca2þ-sensitivity using recombinant TnT K280N (see Fig. 2).
Ratio (EC50 Test/Control) N p TnI Phosphorylation
Test Control
1.7 ± 0.12 6 0.0028 1.6 ± 0.11 1.6 ± 0.11
1.1 ± 0.037 10 0.11 1.6 ± 0.060 0.34 ± 0.19
1.6 ± 0.13 4 0.018 1.6 ± 0.11 1.6 ± 0.11
Fig. 3. Effect of the troponin I phosphorylation on Ca2þ-sensitivity of thin ﬁlaments containing HCM-causing TnT mutations. The fraction of ﬁlaments motile, measured in a
paired experiment by IVMA, is plotted against [Ca2þ] for representative single experiments. The mean values of EC50 from replicate experiments are shown in Table 3. Solid lines and
points, phosphorylated troponin; dotted lines and open points, unphosphorylated troponin. Error bars represent SEM of four measurements of motility in the same motility
chamber. Purple, HCM-causing TnT mutation thin ﬁlaments. The mean values of EC50 from replicate experiments is plotted in Fig. 4B and summarised in Table 3. All of the HCM-
causing mutations tested show uncoupling in the IVMA when phosphorylated and unphosphorylated thin ﬁlaments are compared.
A.E. Messer et al. / Archives of Biochemistry and Biophysics 601 (2016) 113e1201162.3. Quantitative in vitro motility assay (IVMA)
Thin ﬁlaments were reconstituted with 10 nM rabbit skeletal or
mouse cardiac muscle a-actin (labelled with TRITC phalloidin),
tropomyosin (40e60 nM) and troponin (60 nM) to study Ca2þ-
regulation of ﬁlament motility by the quantitative in vitro motility
assay (IVMA) [4,18,25]. Thin ﬁlament movement over a bed of
immobilised rabbit fast skeletal muscle heavymeromyosin (100 mg/
ml) was compared in two channel motility cells in which troponin
varied by a single factor (mutation, phosphorylation state or
treatment with drug). The temperature was set to 29 C. Filament
movementwas recorded and analysed as previously described [26],
yielding two parameters, the fraction of ﬁlaments moving and the
speed of moving ﬁlaments.
The fractionmotile and the sliding speeds weremeasured over a
range of Ca2þ concentrations to generate Ca2þ-activation curves as
shown previously [4,17]. The data were ﬁtted to the 4-variable Hill
equation to yield a value for EC50 and nH. EC50 values from replicate
experiments were analysed by paired t-test since the distribution of
EC50 has been shown to be normal.3. Results
3.1. Human heart sample with TnT K280N mutation
We initially studied a TnT mutation in a unique cardiac muscle
sample from a patient with HCM due to a homozygous mutation in
TnT, K280N. The patient had a septal myectomy but subsequently
required a heart transplant at age 26. The mutation was identiﬁed
and contractility of skinned myocytes was investigated in a previ-
ous study [27].
We isolated troponin from the sample and conﬁrmed that
asparagine had exclusively replaced a lysine at amino acid 280
(K280N) by mass spectrometry (Supplemental data). The TnI
phosphorylation, measured by phosphate afﬁnity SDS-PAGE, was in
the range 1.4e1.6 mols Pi/mol TnI. This is not signiﬁcantly different
from donor heart troponin (Table 1) and substantially greater than
heart samples from septalmyectomy operations, indicating that the
myectomy operation had restored phosphorylation levels to
normal although this did not prevent subsequent heart failure
requiring heart transplant [27].
We investigated the effect of the TnT K280N mutation on
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Fig. 4. Effect of the different HCM-causing TnT mutations on Ca2þ-sensitivity and
its modulation by TnI phosphorylation. Summary of the HCM-causing TnT muta-
tions. Mean EC50 values from replicate paired experiments are plotted, see Table 3.
Error bars are ± SEM. Blue, WT thin ﬁlaments; Blue hatched, unphosphorylated WT
thin ﬁlaments; Purple, HCM-causing TnT mutant thin ﬁlaments; Purple hatched,
unphosphorylated mutant thin ﬁlaments. The previously studied ACTC E99K and TPM1
E180G were included as a comparison. A. All the HCM-causing TnT mutants show
increased Ca2þ-sensitivity (decreased EC50) compared to WT thin ﬁlaments. B. All the
HCM-causing TnT mutants are uncoupled in comparison to WT thin ﬁlaments.
A.E. Messer et al. / Archives of Biochemistry and Biophysics 601 (2016) 113e120 117troponin function in thin ﬁlaments reconstituted with actin and
human cardiac tropomyosin. We used IVMA to study thin ﬁlament
Ca2þ-regulation of unloaded movement over immobilised heavy
meromyosin. When we compared thin ﬁlaments containing donor
heart and TnT K280N patient heart troponin there was no differ-
ence in the Ca2þ-sensitivity or maximum sliding speed (Fig. 1,Table 3
Effect of the HCM related TnT mutations on Ca2þ-sensitivity and phosphorylation depend
TnT mutation EC50 WT
mM ± SEM
EC50 mutant
mM ± SEM
Ratio EC50
WT/mutan
R92Q 0.12 ± 0.013 0.041 ± 0.00091 2.9 ± 0.28
D14 0.22 ± 0.035 0.079 ± 0.0081 2.7 ± 0.16
D28 þ 7 0.097 ± 0.016 0.041 ± 0.0057 2.3 ± 0.06
DE160 0.094 ± 0.0091 0.049 ± 0.0082 2.0 ± 0.30
S179F 0.10 ± 0.0020 0.047 ± 0.00049 2.1 ± 0.02
K273E 0.096 ± 0.0019 0.069 ± 0.024 1.6 ± 0.53
K280N 0.17 ± 0.037 0.10 ± 0.020 1.7 ± 0.12Table 1).
We previously found that this pattern of results was typical of
muscle from the interventricular septum of hypertrophic obstruc-
tive cardiomyopathy (HOCM) patients that generally also had an
uncoupled relationship between Ca2þ-sensitivity and TnI phos-
phorylation accompanied by very low levels of TnI phosphorylation
[23]. We therefore determined the effect of dephosphorylating the
TnT K280N patient troponin on Ca2þ-regulation. In contrast to the
3.1-fold increase in Ca2þ-sensitivity of donor heart troponinwhen it
was dephosphorylated, the Ca2þ-sensitivity of thin ﬁlaments con-
taining TnT K280N patient troponinwas independent of the level of
phosphorylation (Fig. 2, Table 1). We then replaced the TnT in the
TnT K280N patient sample with recombinant wild-type TnT by an
exchange reaction (exchange was 89% [23]) and observed that the
dependence of Ca2þ-sensitivity on TnI phosphorylation was
restored.
In a previous study of troponin from patients with obstructive
HCM, we found that the myoﬁlament Ca2þ-sensitivity was similar
to donor heart troponin, as observed here, and did not change with
TnI phosphorylation level independently of the gene that was
mutated [23]. In order to determine the direct effects of the TnT
K280N mutation, we investigated the effect of recombinant human
cardiac TnT K280N on thin ﬁlament regulation. Comparison of
donor heart troponin and donor heart troponin with the TnT
component replaced by TnT K280N showed that the mutation
increased Ca2þ-sensitivity 1.7-fold; a similar shift in Ca2þ-sensi-
tivity was obtained with 90% and 45% exchanged (Fig. 2, Table 2).
However, the Ca2þ-sensitivity of troponin containing recombinant
TnT K280N did not depend on TnI phosphorylation. The increased
Ca2þ-sensitivity due to recombinant TnT K280N is typical of HCM-
causing mutations in vitro and indicates that the absence of Ca2þ-
sensitivity shift in the patient sample was probably due to sec-
ondary abnormalities similar to troponin from the IVS of HOCM
patients.3.2. HCM-causing TnT mutations studied in transgenic mice
We next examined the HCM-related TnT mutation R92Q in the
tropomyosin binding domain of TnT expressed in mouse models
[19]. The level of mutation expression in these lines is 67%.
Compared to troponin from non-transgenic mouse hearts, the TnT
R92Q mutation increased Ca2þ-sensitivity and uncoupled the
relationship between Ca2þ-sensitivity and TnI phosphorylation
(Figs. 3 and 4, Table 3) [17].3.3. HCM-causing TnT mutations studied using recombinant
troponin
A further ﬁve HCM-causing mutations in TnT were examined
using recombinant troponin expressed as the whole troponin
complex in Escherichia coli. DE160, S179F and K273E are produced
by missense mutations in the TNNT2 gene [28e30]. TnT D14 andence of Ca2þ-sensitivity (see Figs. 3 and 4). All data rounded to 2 signiﬁcant ﬁgures.
t ± SEM
EC50 mutant P
mM ± SEM
EC50 mutant dP
mM ± SEM
Ratio EC50
P/dP
0.072 ± 0.017 0.060 ± 0.012 1.1 ± 0.045
0.055 ± 0.0031 0.055 ± 0.0032 1.0 ± 0.019
8 0.054 ± 0.0041 0.055 ± 0.0037 1.0 ± 0.015
0.052 ± 0.0046 0.053 ± 0.0056 1.0 ± 0.043
0 0.059 ± 0.0030 0.057 ± 0.0038 1.1 ± 0.096
0.059 ± 0.0024 0.056 ± 0.0026 1.1 ± 0.014
0.10 ± 0.0048 0.098 ± 0.0052 1.1 ± 0.037
Fig. 5. Effect of EGCG on the different HCM-causing TnT mutations. A. Effect of EGCG on Ca2þ regulation of thin ﬁlaments containing the TnT R92Q HCM-causing mutation.
Fraction of ﬁlaments motile, measured by IVMA, is plotted against [Ca2þ] for representative experiments. Solid lines and points, phosphorylated troponin; dotted lines and open
points, unphosphorylated troponin. Error bars represent SEM of four measurements of motility in the same motility chamber. Purple, TnT R92Q containing thin ﬁlaments; green, the
presence of 100 mM EGCG. B. The effect of EGCG at a single Ca2þ concentration (0.037 mM, shown by the blue dotted line in Fig. 5A) is plotted for TnT R92Q. C. The effect at 0.037 mM
Ca2þ is plotted for the six other HCM-causing TnT mutations.
A.E. Messer et al. / Archives of Biochemistry and Biophysics 601 (2016) 113e120118D28 þ 7 are the two C-terminal truncation products produced by
the splice-site mutation int15 G1 > A [31]. All of these mutations
increased Ca2þ-sensitivity relative to donor heart troponin as pre-
viously found with ACTC E99K and TPM1 E180G [7e11,13,14,17,32]
(Fig. 4A). All of these mutations fully uncoupled the relationship
between Ca2þ-sensitivity and TnI phosphorylation, Figs. 3 and 4B,
Table 3.
3.4. EGCG can recouple the uncoupled HCM related mutations in
TnT
In a previous study we found that the uncoupling effect of DCM-
causing mutations could be reversed by Epigallocatechin-3-gallate
(EGCG) and related compounds in vitro and inmyoﬁbrils [17]. EGCG
could also restore coupling to the HCMmutations, TPM1 E180G andACTC E99K. We therefore investigated whether EGCG could restore
coupling to HCM related mutations in TnT. Fig. 5A shows that
modulation of Ca2þ-sensitivity by TnI phosphorylation was fully
restored to thin ﬁlaments containing the TnT R92Q mutation. This
is shown by a shift of both curves to the right on addition of 100 mM
EGCG with the phosphorylated curve shifting more to bring back
the difference in Ca2þ-sensitivity due to phosphorylation (as shown
in Fig. 1C). This can also be shown by plotting the difference in
fraction motile at a ﬁxed Ca2þ concentration (Fig. 5B). The other
mutations were tested at a ﬁxed concentration of 0.037 mM Ca2þ
and likewise showed restoration of modulation of Ca2þ-sensitivity
by TnI phosphorylation (Fig. 5C). Thus EGCG is capable of restoring
coupling to every mutant troponin that is uncoupled both in DCM
and HCM.
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Fig. 6. Effect of EGCG on the HCM-causing mutation TnT R92Q. Summary of the
HCM-causing mutation TnT R92Q, EC50 values from replicate paired experiments are
plotted. Error bars represent SEM of four measurements of motility in the same
motility chamber. The TnT R92Q mutation causes the thin ﬁlaments to be uncoupled
and EGCG re-couples the system and brings back the difference in Ca2þ-sensitivity
seen with wild-type (or donor) thin ﬁlaments.
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4.1. Regulatory properties of the homozygous TnT K280N mutant
patient tissue sample
This sample enabled us to study troponin with an HCM related
mutation in TnT in the context of the patient's heart. Contractility in
the same sample has also been studied in skinnedmuscle ﬁbres and
in single myoﬁbrils [33]. Both the isolated troponin and the skinned
muscle ﬁbres indicated that myoﬁlament Ca2þ-sensitivity was not
very different from donor heart controls: the two were indistin-
guishable in IVMAwhilst TnT K280N patient skinned muscle had a
20% higher Ca2þ-sensitivity in skinned ﬁbres. The studies in myo-
ﬁbrils indicated that the kinetics of contraction at saturating Ca2þ
were altered by the mutation, with kACT and slow kREL both being
increased compared to donor heart myoﬁbrils, similar to a previous
studywith an HCMmutation inmyosin, however, Ca2þ dependence
was not measured [34].
Exchange experiments permit the TnT K280N mutation to also
be studied in troponin with a recombinant mutation introduced
into ‘normal’ donor heart troponin. The regulatory properties are
different, indicating that secondary changes have occurred to the
troponin in the HCM patient's heart as previously found by Bayliss
et al. [23]. Recombinant human cardiac TnT K280N increased
myoﬁlament Ca2þ-sensitivity 1.7-fold in the IVMA, as is common
with HCM-causing mutations (Fig. 2, Table 2). It is interesting that
the effect of 95% mutation, a similar level to that found in the pa-
tient, and 45% mutation produced a similar Ca2þ-sensitivity shift,
suggesting that this mutation was dominant negative in common
with most HCM-causing mutations. However, there is no data
available on individuals with a heterozygous TnT K280N mutation
that would allow us to conﬁrm this conclusion.
In contrast to measurements of Ca2þ-sensitivity, the effect of the
mutation on the kinetics of myoﬁbrillar force production and
relaxation at saturating Ca2þ concentrations showed that exchange
of recombinant human cardiac TnT K280N into donor and also of
wild-type troponin into TnT K280N patient myoﬁbrils gave fully
reversible effects [33]. Since IVMA measures unloaded movement
at 29 C, whilst studies on myoﬁbrils or permeabilised cells mea-
sure isometric force only at saturating Ca2þ at 15 C, the studies are
not directly comparable as we discussed previously [17] and
therefore not contradictory.
The patient sample is unusual since the HCM phenotype was
found with a high level of TnI phosphorylation, equivalent to donor
heart muscle. Previously HCM was studied in tissue from septal
myectomies that always had a very low level of phosphorylation of
both TnI and MyBP-C [24,35,36]. Since the patient had a myectomy
prior to the transplant it seems likely that the operation was
beneﬁcial to the septum, as determined by the TnI phosphorylation
level, but the disease-causing mutation remained and it was still
uncoupled (as is the case with DCM). The myectomy did not pre-
vent subsequent heart failure, perhaps due to diastolic dysfunction.
When we tested the Ca2þ sensitivity at high and low levels of
phosphorylation there was no difference, i.e. the troponin was
uncoupled. This is similar to ﬁndings in myectomy samples where
uncoupling was independent of the HCM-causing mutations [23].
When we repeated the test with donor troponin exchanged with
recombinant human cardiac TnT K280N, Ca2þ-sensitivity was still
uncoupled, so in this case a single pointmutation in TnT is sufﬁcient
to uncouple Ca2þ-sensitivity from TnI phosphorylation.
4.2. Uncoupling is a common feature of HCM related mutations in
TnT
An important question addressed in this manuscript is whetherall mutations in TnT that are associated with HCM are uncoupled.
We therefore examined six additional well-characterised HCM-
linked mutations in TnT and found that they all increased Ca2þ-
sensitivity as previously reported [22,37e40], and all exhibited
uncoupling of Ca2þ-sensitivity from TnI phosphorylation levels. The
mutant TnT R92Q troponin extracted from transgenic mice,
expressed at 65% [19], and the ﬁve TnT mutations studied using
recombinant troponin were all fully uncoupled. Therefore, muta-
tions in TnT join mutations in TnI (R145G and R21C, measured by
ATPase, IVMA and in myoﬁbrils and skinned ﬁbres and K206Q,
measured by ATPase and IVMA), TnC (L29Q, measured by IVMA and
ATPase and Y5H, I148V and M103I, measured in skinned papillary
muscle), actin (E99K, measured by IVMA and in myoﬁbrils) and
tropomyosin (E180G, measured by IVMA) as mutations demon-
strated to cause uncoupling in vitro [7e11,13,14,17,32,41]. Thus, for
HCM-causing mutations in genes coding for sarcomeric thin ﬁla-
ment proteins, Ca2þ-sensitisation together with uncoupling in vitro
is likely to be a common consequence and they may contribute to
the HCM phenotype.
We recently demonstrated that EGCG and related compounds
could restore coupling to DCM-causing mutations in thin ﬁlament
proteins [17]. We now show that EGCG can also restore coupling to
all the uncoupled HCM-causing TnT mutations. Re-coupling by
EGCGwas also observed for ACTC E99K and TPM1 E180G suggesting
a common mechanism [17]. In fact the combination of Ca2þ-
desensitisation and re-coupling reverses both the abnormalities
found in troponin with an HCM mutation. This is illustrated for the
TnT R92Q mutation where the EGCG treatment fully restores
motility to the levels of wild-type Ca2þ-sensitivity and phosphor-
ylation dependence (Fig. 6). This suggests a potential use for re-
coupling compounds based on EGCG as treatment for HCM.
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